Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Melanoma 2Endometrial Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Clear-cell metastatic renal cell carcinoma 1Cirrhosis, Familial, with Pulmonary Hypertension 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1Bone Neoplasms 1Advanced Malignancies 1Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1Adenocarcinoma 1

Interventions

lenvatinib 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Gemcitabine 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × lenvatinib × 30 days × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡